The analysis found no statistically significant increase in overall cancer risk, with a pooled risk ratio of 0.98 (95% CI 0.83-1.15), indicating similar cancer rates between GLP-1-treated patients and control groups
Weight Loss Lose up to 1520% of your body weight with proper use Accountability Weekly check-ins ensure accountability and safe progress No crash diets or stimulants just real, metabolic change Improved Levels Improved blood sugar levels and cholesterol in many patients What Results Can You Expect
Is refrigeration necessary for tirzepatide before first use
Why Wegovy (semaglutide) and Mounjaro (tirzepatide) arent magic jabs for weight loss Like other drugs in the GLP-1 family, Wegovy and Mounjaro are medications that make it easier to lose weight and stick to healthy habitsbut they don't produce weight loss on their own
While many executives, investors, and analysts have shown excitement towards this new entity, the announcement has sent a ripple effect across regulators, health technology leaders, and early-stage investors
The SURMOUNT-5 trial (NEJM, 2025) found that tirzepatide produced an average weight loss of 20.2% versus 13.7% for semaglutide over 72 weeks a clinically meaningful difference
